Wednesday, December 15, 2021

ASH Review: Mosunetuzumab (Bi-Specific) for FL

›
As I have said a couple of times, there weren't really any game-changing presentations at ASH for Follicular Lymphoma. But the one that ...
1 comment:
Saturday, December 11, 2021

No More Duvelisib for Follicular Lymphoma

›
Taking a quick break from ASH reports to talk about some news from earlier in the week: The maker of the PI3K Inhibitor Duvelisib has taken ...
2 comments:
Monday, December 6, 2021

ASH Preview: R-Squared (Lenalidomide + Rituximab)

›
As I said a few weeks ago, I was surprised at how many ASH presentations this ear are focusing on Lenalidomide (also known as Revlimid), eit...
Wednesday, December 1, 2021

ASH: Why Do Some FL Patients Do Well with Only Rituxan?

›
We're on to another ASH preview. This one is for the presentation called " 3500 Follicular Lymphoma Microenvironment Signatures D...
6 comments:
Saturday, November 27, 2021

ASH Preview: Rituxan Maintenance

›
Here we go -- time to start looking at some of the Follicular Lymphoma abstracts from this year's ASH conference . Before I get into the...
Tuesday, November 23, 2021

Oncologist Appointment

›
I had a six month oncologist appointment today. Everything continues to look good.  As usual, I went to the hospital early to get my blood t...
4 comments:
Wednesday, November 17, 2021

ASH Abstracts are Here!

›
It's that time of year again -- the ASH conference is coming up soon, and the abstracts are now online. ASH is the American Society of H...